(Q36226112)

12 August 2017

1 reference

title

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside (English)

1 reference

12 August 2017

1 reference

Bruno B

1

1 reference

12 August 2017

Giaccone L

2

1 reference

12 August 2017

Rotta M

3

1 reference

12 August 2017

Anderson K

4

1 reference

12 August 2017

Boccadoro M

5

1 reference

12 August 2017

publication date

1 October 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

19

1 reference

12 August 2017

issue

10

1 reference

12 August 2017

page(s)

1729-1738

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403905

12 August 2017

exact match

0 references

cites work

Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

New drugs for treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Genetics and cytogenetics of multiple myeloma: a workshop report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thalidomide for previously untreated indolent or smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Clinical update: proteasome inhibitors in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Bortezomib in combination with dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Multiple myeloma biology: lessons from the 5TMM models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403905

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403905

1 reference

release_ypc6sxveqvhdzacgauwlmkzyoi

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ypc6sxveqvhdzacgauwlmkzyoi

24 November 2022

mapped directly with Wikidata item

1 reference